Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Vaine M, Wang S, Hackett A, Arthos J, Lu S.

Vaccine. 2010 Apr 9;28(17):2999-3007. doi: 10.1016/j.vaccine.2010.02.006. Epub 2010 Feb 17.

2.

Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.

3.

Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.

Rangasamy SP, Menon V, Dhopeshwarkar P, Pal R, Vaniambadi KS, Mahalingam S.

Vaccine. 2016 May 5;34(21):2444-2452. doi: 10.1016/j.vaccine.2016.03.062. Epub 2016 Mar 28.

PMID:
27032514
4.

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S.

J Virol. 2008 Aug;82(15):7369-78. doi: 10.1128/JVI.00562-08. Epub 2008 May 21.

5.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.

J Virol. 2016 Mar 28;90(8):4133-49. doi: 10.1128/JVI.03135-15. Print 2016 Apr.

6.
7.

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S.

J Virol. 2016 Oct 28;90(22):10362-10378. Print 2016 Nov 15.

8.

Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.

Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R.

J Gen Virol. 2011 Jan;92(Pt 1):128-40. doi: 10.1099/vir.0.023242-0.

9.

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL.

J Virol. 1998 Nov;72(11):9092-100.

10.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

11.

Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.

Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL.

Vaccine. 2005 Mar 31;23(19):2454-64.

PMID:
15752831
12.

Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".

Wang Z, Wang SX, Liu SY, Bao ZY, Zhuang DM, Li L, Zhang CH, Zhang L, Li JY, Lu S.

Chin Med J (Engl). 2009 Oct 5;122(19):2339-45.

PMID:
20079137
13.

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nádas A, Cohen S, Totrov M, Seaman MS, Wang S, Lu S.

J Virol. 2011 Oct;85(19):9887-98. doi: 10.1128/JVI.05086-11. Epub 2011 Jul 27.

15.

DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.

Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, Wang S, Lu S.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1630-7. doi: 10.4161/hv.21648. Epub 2012 Oct 30.

16.

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Pissani F, Malherbe DC, Schuman JT, Robins H, Park BS, Krebs SJ, Barnett SW, Haigwood NL.

Vaccine. 2014 Jan 16;32(4):507-13. doi: 10.1016/j.vaccine.2013.11.022. Epub 2013 Nov 23.

17.

Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Liu L, Hao Y, Luo Z, Huang Y, Hu X, Liu Y, Shao Y.

Vaccine. 2012 Jun 13;30(28):4135-43. doi: 10.1016/j.vaccine.2012.04.075. Epub 2012 May 2.

18.

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.

Leung L, Srivastava IK, Kan E, Legg H, Sun Y, Greer C, Montefiori DC, zur Megede J, Barnett SW.

AIDS. 2004 Apr 30;18(7):991-1001.

PMID:
15096801
19.
20.

Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine.

Pouliot K, Buglione-Corbett R, Marty-Roix R, Montminy-Paquette S, West K, Wang S, Lu S, Lien E.

Vaccine. 2014 Sep 3;32(39):5049-56. doi: 10.1016/j.vaccine.2014.07.010. Epub 2014 Jul 18.

PMID:
25045815

Supplemental Content

Support Center